Full Year 2025 PureTech Health PLC Earnings Call Transcript

Apr 29, 2026 / 01:00 PM GMT

Release Date Price: $17.4 (-4.08%)

Transcript

Key Points

Positve

PureTech Health PLC (PTCHF) has a proven innovation model that translates into greater shareholder value by targeting molecules with validated pharmacology, reducing technical risk and improving the probability of success.
The company has developed three FDA-approved therapeutics, including CODEMC for schizophrenia, demonstrating meaningful clinical and regulatory success.
PureTech Health PLC (PTCHF) has a diversified pipeline and has generated over a billion in growth from monetization of its founded entities.
The company plans to return a greater proportion of future cash generation to shareholders, enhancing capital discipline and flexibility.
Positive top-line data from the Phase 1B trial of LYT200 in Gallup Oncology indicates strong potential for advancing treatment in relapse-refractory high-risk MDS.

Negative

PureTech Health PLC (PTCHF) reported a net loss of $110.1 million for 2025, compared to a net income of $27.8 million in 2024, primarily due to the absence of a one-time gain from the seaport deconsolidation.
The company is voluntarily delisting from NASDAQ, which may limit its exposure to certain investor bases.
There is a reliance on external capital for the development of founded entities, which could pose risks if funding is not secured.
The company's revenues are mostly driven by milestone-based payments and royalties, which can fluctuate significantly from year to year.
PureTech Health PLC (PTCHF) does not expect material financial returns from its legacy holdings, which may impact overall value.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PRTC.L - PureTech Health PLC
Full Year 2025 PureTech Health PLC Earnings Call
Apr 29, 2026 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Greetings and welcome to the PureTech Health 2025 Annual Results Conference Call. At this time, all participants are in a listen-only mode.

After the speakers' prepared remarks, there will be a question-and-answer session and instructions will follow at that time.

As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Alison Mee Taubet, Senior Vice President of Communications.

Thank you, Alison. You may begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, everyone, for joining us for

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.